Hebang Biotechnology: In the first half of 2026, the net profit reached 380 million yuan, a year-on-year increase of 634.30%.

Hepalink Bio announced that in the first half of 2026, operating revenue reached 2.888 billion yuan, a year-on-year decrease of 26.34%; net profit attributable to shareholders was 380 million yuan, a year-on-year increase of 634.30%; and net profit excluding non-recurring items was 375 million yuan, a year-on-year increase of 698.33%. In the same period last year, the net profit was 51.715 million yuan. No profit distribution or transfer of reserves to increase share capital was conducted during this reporting period.